Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Fuji
AstraZeneca
McKesson
Express Scripts
Baxter
McKinsey
Johnson and Johnson
Merck

Generated: August 21, 2017

DrugPatentWatch Database Preview

Pfizer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER INC, and what generic alternatives to PFIZER INC drugs are available?

PFIZER INC has eleven approved drugs.

There are twenty-five US patents protecting PFIZER INC drugs on PFIZER INC drugs in the past three years. There is one tentative approval on PFIZER INC drugs.

There are six hundred and twenty-nine patent family members on PFIZER INC drugs in seventy countries.

Summary for Applicant: Pfizer Inc

Patents:25
Tradenames:11
Ingredients:11
NDAs:11
Drug Master File Entries: (click here to view)73
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
QUILLICHEW ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
XELJANZ XR
tofacitinib citrate
TABLET, EXTENDED RELEASE;ORAL208246-001Feb 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Inc
TROXYCA ER
naltrexone hydrochloride; oxycodone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL207621-002Aug 19, 2016RXNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pfizer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc
NICOTROL
nicotine
SPRAY, METERED;NASAL020385-001Mar 22, 1996► Subscribe► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-001Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-001Jun 14, 1996► Subscribe► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
GEODON
ziprasidone hydrochloride
SUSPENSION;ORAL021483-001Mar 29, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PFIZER INC drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinib
Extended-release Tablets11 mg
XELJANZ XR
11/7/2016
varenicline tartrate
Tablets0.5 mg and 1 mg
CHANTIX
5/10/2010
ziprasidone hydrochloride
Capsules20 mg, 40 mg, 60 mg and 80 mg
GEODON
2/7/2005
sildenafil citrate
Tablets25 mg and 50 mg
VIAGRA
11/19/2004
sildenafil citrate
Tablets100 mg
VIAGRA
10/25/2004
irinotecan hydrochloride
Injection20 mg/mL, 2 mL and 5 mL vials
CAMPTOSAR
7/26/2004

Non-Orange Book Patents for Pfizer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
7,601,727Pyrrolo[2,3-d]pyrimidine compounds► Subscribe
7,842,699Pyrrolo[2,3-D]pyrimidine compounds► Subscribe
8,465,765Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
8,747,902Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pfizer Inc Drugs

Country Document Number Estimated Expiration
Poland333737► Subscribe
Czech Republic20033260► Subscribe
Ukraine66825► Subscribe
Ukraine74813► Subscribe
Bulgaria64691► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pfizer Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
5Finland► Subscribe
0170012 00212Estonia► SubscribePRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
2008 00031Denmark► Subscribe
0355Netherlands► Subscribe300355, 20181113, EXPIRES: 20220425
0863Netherlands► SubscribePRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, ESTER, AMIDE OF PROMEDICIJN DAARVAN; REGISTRATION NO/DATE: EU/1/16/1147 20161111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Colorcon
Healthtrust
Express Scripts
Covington
McKesson
Cipla
Chubb
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot